hydrophobic), most commonly used diabetes drugs (metformin, insulins, sulfonylureas, and thiazolidinediones), PPIs, 5 alpha reductase inhibitors, and alpha blockers. Time-dependent Cox regression proportional hazards models were performed determine predictors of PC diagnosis. Medication exposure was time-varying and modeled as "ever" vs. "never" use or as cumulative exposure.
INTRODUCTION AND OBJECTIVES:
To evaluate Metabolic syndrome (MetS) as a risk factor of Prostate cancer (PC) in patient undergone to repeat trans-rectal prostate biopsy (PB).
METHODS: Between May 2010 and October 2018 a prospective cohort study was carried out by enrolling patients underwent to repeat biopsy for persistence of clinical suspicious of PC: PSA! 4 ng/ ml, suspect digital rectal examination findings, more than three biopsy cores with High Grade Prostatic Intraepithelial Neoplasia (wHGPIN). PSA!20 ng/ml was the main exclusion criteria. PB was performed by six months of the initial one. A 12-14 core prostate biopsy template was used in both biopsies. MetS was defined according to the Adult Treatment Panel III criteria. A binary logistic model was computed to assess risk factors of PC on re-biopsy. A nomogram was generated to predict PC. Accuracy was evaluated using the L- with a net benefit in the range of probability between 10% an 45% (figure 1).
CONCLUSIONS: In our patients MetS was an independent predictor of PC and particularly of high grade PC, confirming the importance of evaluating metabolic factors in patients at risk of prostate cancer. Our model if validated and could be used to reduce the number of unnecessary biopsy in patients with a previous negative biopsy.
Source of Funding: None

MP18-06 CLINICOPATHOLOGIC IMPLICATIONS OF ATYPICAL SMALL ACINAR PROLIFERATION (ASAP) IN THE ERA OF ACTIVE SURVEILLANCE
Lucas W. Dean*, Hikmat A. Al-Ahmadie, Ying-Bei Chen, Anuradha Gopalan, S. Joseph Sirintrapun, Satish K. Tickoo, Victor E. Reuter, Samson W. Fine, New York, NY INTRODUCTION AND OBJECTIVES: The diagnosis of atypical small acinar proliferation (ASAP) on prostatic needle biopsy (NB) is associated with a 30-40% cancer detection rate on subsequent NB. In the era of active surveillance, many men with low risk disease are managed expectantly. The percentage of cancers of low-grade and low-volume (LG/LV: Gleason score (GS) 3þ3[6, 3 cores, 60% of any core) detected after an ASAP diagnosis is not well-studied. We evaluated follow-up NB pathology findings in patients with an initial ASAP diagnosis, including a subset who went on to radical prostatectomy (RP).
METHODS: We identified 167 patients with an ASAP diagnosis on their first NB at our institution over a 13-year period. 70/167 had at least one follow-up NB. We determined number of follow up NB, pathologic findings in each NB and highest grade/quantity of cancer detected. 16/70 subsequently underwent RP and pathologic results were also reviewed.
RESULTS: Of 70 patients, 48 (69%) had 1 follow-up NB, 13 (19%) had 2 and 9 (14%) had >2 (range: 3-6). Median followup from initial ASAP diagnosis in men who did not undergo radical treatment was 4.8 years. 28/70 (40%) patients had cancer on their first repeat Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e265
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